Graft Vs Host Disease: Understanding The ICD-10 Codes

What is Graft vs Host Disease ICD 10?

Graft vs Host Disease (GVHD) is a condition that can occur after a stem cell or bone marrow transplant. It is a complication where the donor cells attack the recipient’s body. In the context of medical coding, GVHD is assigned the ICD-10 code T86.01.

Code Information

Graft-versus-Host-Reaktion - DocCheck Flexikon
Graft-versus-Host-Reaktion – DocCheck Flexikon

The ICD-10 code T86.01 is used to classify cases of GVHD in patients who have undergone a transplant. This code is essential for medical billing and documentation purposes, as it allows healthcare providers to accurately record and track instances of this condition.

Diagnostic Related Groups (MS-DRG)

Klinische Versorgung der chronischen Graft-versus-Host-Krankheit
Klinische Versorgung der chronischen Graft-versus-Host-Krankheit

GVHD falls under MS-DRG 016, which covers complications of treatment with a principal diagnosis of Bone Marrow Transplant. This DRG helps classify cases of GVHD for reimbursement and resource allocation purposes.

Convert to ICD-9 Code

Graft Vs
Graft Vs

Prior to the implementation of ICD-10, GVHD was classified under the ICD-9 code 279.50. It is important to convert older records to the new ICD-10 coding system for accurate and up-to-date documentation.

Code History

ICD--CM Diagnosis Code D
ICD–CM Diagnosis Code D

The ICD-10 code T86.01 for GVHD was introduced as part of the ICD-10 code set on October 1, 2015. This code replaced the previous ICD-9 code 279.50 for GVHD, aligning with the updated coding guidelines and terminology.

Approximate Synonyms

Other terms that may be used to refer to GVHD include allogeneic graft-versus-host disease and alloimmune disease. These synonyms are important for accurately capturing and documenting instances of this condition in medical records.

Clinical Information

GVHD is a serious and potentially life-threatening condition that can affect various organ systems in the body. It typically occurs when the donor’s immune cells recognize the recipient’s tissues as foreign and mount an immune response against them.


The primary cause of GVHD is the transplant of donor cells that recognize the recipient’s tissues as foreign. This triggers an immune response that can lead to widespread inflammation and tissue damage throughout the body.


The symptoms of GVHD can vary depending on the severity and organs affected. Common symptoms may include skin rash, gastrointestinal issues, liver dysfunction, and respiratory problems. Severe cases of GVHD can be life-threatening.


Diagnosing GVHD typically involves a thorough medical history, physical examination, and laboratory tests to assess organ function and immune response. Biopsies of affected tissues may also be performed to confirm the diagnosis.


Treatment for GVHD often involves immunosuppressive medications to suppress the immune response and reduce inflammation. In severe cases, additional therapies such as phototherapy, steroids, or biologic agents may be needed to manage symptoms and prevent complications.


In conclusion, Graft vs Host Disease ICD 10 (T86.01) is a serious condition that can occur after a stem cell or bone marrow transplant. Proper coding and documentation of GVHD are essential for accurate medical billing, reimbursement, and tracking of this potentially life-threatening complication.


Q: Can GVHD be prevented?
A: While GVHD cannot always be prevented, healthcare providers may use strategies such as matching donor and recipient tissue types to reduce the risk.

Q: How common is GVHD?
A: GVHD occurs in a significant proportion of patients who undergo stem cell or bone marrow transplants, with varying degrees of severity.

Q: Is GVHD treatable?
A: Yes, GVHD can be treated with immunosuppressive medications and supportive care to manage symptoms and improve outcomes.

Q: Can GVHD recur after treatment?
A: Recurrence of GVHD is possible, especially in cases of chronic or severe disease. Close monitoring and follow-up care are essential for managing recurrent GVHD.

Q: Are there any long-term complications of GVHD?

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button